These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18834580)

  • 1. Relation of response to treatment with dorzolamide in X-linked retinoschisis to the mechanism of functional loss in retinoschisin.
    Walia S; Fishman GA; Molday RS; Dyka FM; Kumar NM; Ehlinger MA; Stone EM
    Am J Ophthalmol; 2009 Jan; 147(1):111-115.e1. PubMed ID: 18834580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis.
    Genead MA; Fishman GA; Walia S
    Arch Ophthalmol; 2010 Feb; 128(2):190-7. PubMed ID: 20142541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of dorzolamide for patients with X-linked retinoschisis.
    Apushkin MA; Fishman GA
    Retina; 2006 Sep; 26(7):741-5. PubMed ID: 16963845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolution of mid-peripheral schisis in x-linked retinoschisis with the use of dorzolamide.
    Collison FT; Genead MA; Fishman GA; Stone EM
    Ophthalmic Genet; 2014 Jun; 35(2):125-7. PubMed ID: 23514609
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo imaging reveals novel aspects of retinal disease progression in Rs1h(-/Y) mice but no therapeutic effect of carbonic anhydrase inhibition.
    Zhour A; Bolz S; Grimm C; Willmann G; Schatz A; Weber BH; Zrenner E; Fischer MD
    Vet Ophthalmol; 2012 Sep; 15 Suppl 2():123-33. PubMed ID: 22672048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dramatic regression of macular and peripheral retinoschisis with dorzolamide 2 % in X-linked retinoschisis: a case report.
    Sadaka A; Sisk RA
    J Med Case Rep; 2016 Jun; 10(1):142. PubMed ID: 27246168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. X-linked retinoschisis maculopathy treated with topical dorzolamide, and relationship to genotype.
    Khandhadia S; Trump D; Menon G; Lotery AJ
    Eye (Lond); 2011 Jul; 25(7):922-8. PubMed ID: 21527955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome.
    Genead MA; Fishman GA
    Arch Ophthalmol; 2010 Sep; 128(9):1146-50. PubMed ID: 20837798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathology of X linked retinoschisis: mutations interfere with retinoschisin secretion and oligomerisation.
    Wang T; Zhou A; Waters CT; O'Connor E; Read RJ; Trump D
    Br J Ophthalmol; 2006 Jan; 90(1):81-6. PubMed ID: 16361673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STELLATE NONHEREDITARY IDIOPATHIC FOVEOMACULAR RETINOSCHISIS: RESPONSE TO TOPICAL DORZOLAMIDE THERAPY.
    Ajlan RS; Hammamji KS
    Retin Cases Brief Rep; 2019; 13(4):364-366. PubMed ID: 28557864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dramatic response to topical dorzolamide in X-linked retinoschisis.
    Thangavel R; Surve A; Azad S; Kumar V
    Indian J Ophthalmol; 2020 Jul; 68(7):1466-1467. PubMed ID: 32587200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of topical and systemic carbonic anhydrase in the treatment of chromosome X-linked retinoschisis.
    Rocha Cabrera P; Pareja Ríos AC; Cordovés Dorta L; Mantolán Sarmiento C; Serrano García MA
    Arch Soc Esp Oftalmol; 2014 Aug; 89(8):320-3. PubMed ID: 24269421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of topical dorzolamide and ketorolac treatment for cystoid macular edema in retinitis pigmentosa and Usher's syndrome.
    Lemos Reis RF; Moreira-Gonçalves N; Estrela Silva SE; Brandão EM; Falcão-Reis FM
    Ophthalmologica; 2015; 233(1):43-50. PubMed ID: 25428176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexpression and interaction of wild-type and missense RS1 mutants associated with X-linked retinoschisis: its relevance to gene therapy.
    Dyka FM; Molday RS
    Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2491-7. PubMed ID: 17525175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of topical dorzolamide for patients with X-linked juvenile retinoschisis: case report.
    Bastos AL; Freitas Bde P; Villas Boas O; Ramiro AC
    Arq Bras Oftalmol; 2008; 71(2):286-90. PubMed ID: 18516436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diurnal variations of foveoschisis by optical coherence tomography in patients with RS1 X-linked juvenile retinoschisis.
    Abalem MF; Musch DC; Birch DG; Pennesi ME; Heckenlively JR; Jayasundera T
    Ophthalmic Genet; 2018 Aug; 39(4):437-442. PubMed ID: 29902095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOPICAL CARBONIC ANHYDRASE INHIBITORS IN THE LONG-TERM TREATMENT OF JUVENILE X-LINKED RETINOSCHISIS.
    Schmitt MA; Wang K; DeBenedictis MJ; Traboulsi EI
    Retina; 2022 Nov; 42(11):2176-2183. PubMed ID: 35982512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa.
    Liew G; Moore AT; Webster AR; Michaelides M
    Invest Ophthalmol Vis Sci; 2015 Feb; 56(3):1531-6. PubMed ID: 25670491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa.
    Grover S; Apushkin MA; Fishman GA
    Am J Ophthalmol; 2006 May; 141(5):850-8. PubMed ID: 16546110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Genetic Study of X-Linked Juvenile Retinoschisis in the Czech Population.
    Kousal B; Hlavata L; Vlaskova H; Dvorakova L; Brichova M; Dubska Z; Langrova H; Vincent AL; Dudakova L; Liskova P
    Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.